ONES Grant: CXCL10/CXCR3 Regulation of Ozone-Induced Epithelial Permeability

NCT03599206 | Completed Early Phase 1 Results FDA Drug

• 1 other identifier: Pro00088966
• Study Type: interventional
• Target: 14
• Locations: 1 country
• Sites: 1

Brief Summary

The purpose of this research study to understand how environmental and genetic factors may be involved in lung function. Study participants will undergo a 1-day screening that includes a blood draw and breathing testing, return for a two-day series of testing to include blood draw, and brief breathing test before and after an inhaled challenge with either filtered air (FA) or ozone (O3). Participants return the next day for a brief breathing test, a blood draw and a procedure called bronchoscopy to evaluate the lung after the challenge. Participants then return 18 - 20 days later to repeat the two-day series of testing to be challenged with the exposure not received on the first series, (FA or O3). Each visit will take about 3 - 3.5 hours. Follow-up phone calls from the study team will occur at 24 hours after each 2-day test series. Total study duration is about one to one-and a half months.

Conditions

Environmental and Genetic Factors on Lung Function

Keywords

genetic: CXCR3 polymorphism rs2280964

Outcome Measures

Primary Outcomes (2)

• Change in Ozone (O3) Induced Epithelial Permeability, as Measured by the Level of Clara Cell Secretory Protein

  This measure is defined by the comparing each individuals baseline (following filtered air challenge) to the ozone response. The investigators will perform two tests on this response as a means of confirmation. The individual will have blood drawn to obtain serum and a bronchoscopy to obtain bronchoalveolar lavage. The serum will be used to determine the level of clara cell secretory protein. This is measured by enzyme-linked immunosorbent assay (ELISA). The value is reported as ng/mL.

  Baseline, 21 days

• Change in Ozone (O3) Induced Epithelial Permeability, as Measured by Albumin Level (ug/mL)

  This measure is defined by the comparing each individuals baseline (following filtered air challenge) to the ozone response. The investigators will perform two tests on this response as a means of confirmation. The individual will have blood drawn to obtain serum and a bronchoscopy to obtain bronchoalveolar lavage. The bronchoalveolar lavage will be similarly used to define the albumin level. Albumin is also measured by ELISA. The value is reported at ug/mL.

  Baseline, 21 days

Secondary Outcomes (5)

• Change in Ozone O3 Induced Alterations in Gene Expression of Airway Epithelial Cells, and Bronchoalveolar Lavage Cells

  Baseline, 21 days

• Change in Ozone (O3) Induced Bronchoalveolar Lavage CXCL11 Levels

  Baseline, 21 days

• Change in Ozone (O3) Induced Bronchoalveolar Lavage CXCL10 Levels

  Baseline, 21 days

• Change in Ozone (O3) Induced Bronchoalveolar Lavage IFN-γ Levels

  Baseline, 21 days

• Change in Ozone (O3) Induced Bronchoalveolar Lavage CXCL9 Levels

  Baseline, 21 days

Study Arms (2)

Ozone

EXPERIMENTAL

Drug: Ozone

Filtered Air

PLACEBO COMPARATOR

Other: Filtered Air

Interventions

Ozone DRUG

Subjects will perform alternating 15 minutes rest with 15 minutes treadmill walk exercise periods for 135 minutes in while breathing Ozone (O3).

Ozone

Filtered Air OTHER

Subjects will perform alternating 15 minutes rest with 15 minutes treadmill walk exercise periods for 135 minutes in while breathing filtered air.

Filtered Air

Eligibility Criteria

• Age: 18 Years - 45 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64)

You may qualify if:

• Prior enrollment in the NIEHS Environmental Polymorphism Registry located in the greater Raleigh-Durham area
• Wild type or homozygous (female)/hemizygous (male - since sex-linked) expression of the CXCR3 polymorphism rs2280964

You may not qualify if:

• Current smokers of tobacco products including e-cigarettes or those with previous smoking history within the prior 5 years
• BMI less than 37 kg/m2
• Pregnant women and women who are presently lactating.
• Subjects that have received antibiotic administration or an upper respiratory infection within the previous 4 weeks
• College and graduate students or employees who are under direct supervision by any of the investigators in this protocol
• Alcohol or illicit substance abuse
• Chronic cardio/pulmonary respiratory disorders or other medical conditions as determined by the investigator
• Increased airway hyperresponsiveness at baseline as measured by a positive methacholine challenge response (methacholine PC20 FEV1 \< 8 mg/ml)
• Subjects will be requested to refrain from antihistamines, nonsteroidal anti-inflammatory agents, antioxidants (e.g. beta-carotene, selenium, and lutein) and supplemental vitamins (e.g. C and E), for 1 week prior to, and during testing.

Sponsors & Collaborators

• Robert Tighe, MD: lead

Study Sites (1)

Duke Asthma, Allergy, and Airway Center

Durham, North Carolina, 27705, United States

Location

MeSH Terms

Interventions

Ozone

Intervention Hierarchy (Ancestors)

Oxygen; Gases; Inorganic Chemicals

Results Point of Contact

• Title: Robert M. Tighe, MD
• Organization: Duke University

robert.tighe@duke.edu

919-684-4894

Study Officials

• Robert Tighe, MD

  Duke University

  PRINCIPAL INVESTIGATOR

Publication Agreements

• PI is Sponsor Employee: Yes

Study Design

• Study Type: interventional
• Phase: early phase 1
• Allocation: RANDOMIZED
• Masking: SINGLE
• Who Masked: PARTICIPANT
• Purpose: OTHER
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR INVESTIGATOR
• PI Title: Associate Professor of Medicine

Study Record Dates

• First Submitted: July 3, 2018
• First Posted: July 26, 2018
• Study Start: August 16, 2019
• Primary Completion: November 29, 2023
• Study Completion: January 24, 2024
• Last Updated: June 15, 2026
• Results First Posted: June 15, 2026

Record last verified: 2026-06

Data Sharing

• IPD Sharing: Will not share

Locations

US (1)